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Venous thromboembolism, which includes deep venous thrombosis and pulmonary 
embolism, is a potentially preventable condition in children. In adults, pharmacologic 
prophylaxis has been shown to significantly reduce the incidence of venous 
thromboembolism in distinct patient cohorts. However, pediatric randomized controlled 
trials have failed to demonstrate the efficacy of pharmacologic prophylaxis against 
thrombosis associated with central venous catheters, the most important risk factor for 
venous thromboembolism in children. Despite the lack of supporting evidence, hospital-
based initiatives are being undertaken to try to prevent venous thromboembolism in 
children. In this study, we sought to review the published guidelines on the prevention 
of venous thromboembolism in hospitalized children. We identified five guidelines, 
all of which were mainly targeted at adolescents and used various risk-stratification 
approaches. In low-risk children, ambulation was the recommended prevention 
strategy, while mechanical prophylaxis was recommended for children at moderate risk 
and pharmacologic and mechanical prophylaxis were recommended for the high-risk 
group. The effectiveness of these strategies has not been proven. In order to determine 
whether venous thromboembolism can be prevented in children, innovative clinical 
trial designs are needed. In the absence of these trials, guidelines can be a source of 
valuable information to inform our practice.
Keywords: child, deep venous thrombosis, guideline, heparin, pulmonary embolism, prophylaxis, randomized 
controlled trial
BACKGROUnD
In the past decade, the incidence of venous thromboembolism (VTE) in children has steadily 
increased. On average, the incidence increased by nearly 10% per year (1). VTE, which is composed 
mainly of deep venous thrombosis (DVT) and pulmonary embolism (PE), is associated with pro-
longed duration of mechanical ventilation and prolonged stay in the pediatric intensive care unit 
(PICU) and in the hospital (2). The excess hospital stay drives the increased cost associated with VTE 
in hospitalized children (3). In some cases, VTE may lead to death (4). The increasing incidence of 
VTE in children is thought to be the result of improved survival in critically ill children (1). It is also 
likely that a heightened awareness of VTE has contributed to increased diagnosis.
Hospital-acquired VTE is preventable in adults (5–7). Multiple randomized controlled trials 
(RCTs) in adults have demonstrated the superiority of pharmacologic prophylaxis, compared to 
TABle 1 | Characteristics of published guidelines for thromboprophylaxis in children.
Reference Target 
population
Risk categories Criteria interventions
Braga and 
Young (10)
Children in 
the pediatric 
intensive care 
unit (PICU)
Low risk Immobility Early mobilization and adequate hydration
At risk ≥1 additional risk factor for VTE Mechanical prophylaxis, pharmacologic 
prophylaxis to be considered for children with 
burns
Raffini et al. (11) Children 
≥14 years old
Low risk No risk factors for VTE Early ambulation
At risk ≥1 risk factor (excluding immobility) or immobility without 
other risk factors for VTE
Mechanical prophylaxis
High risk Immobility with ≥1 additional risk factor for VTE Mechanical and (strong consideration) 
pharmacologic prophylaxis
Hanson  
et al. (12)
Children 
admitted to 
the PICU after 
trauma
Low risk of VTE <13 years old and ≤3 risk factors for VTE None
High risk of VTE 
with high risk of 
bleeding
≥13 years old or <13 years old with ≥4 risk factors for 
VTE and ≥1 risk factor for bleeding
Mechanical prophylaxis and surveillance ultrasound
High risk of VTE 
with low risk of 
bleeding
≥13 or <13 years old with ≥4 risk factors for VTE and no 
risk factor for bleeding
Mechanical and pharmacologic prophylaxis
Meier et al. (14) Children 
10–17 years old
Low risk No risk factors for VTE Early ambulation and mitigation of risk factors
Moderate risk ≥1 risk factor for VTE (excluding immobility) or immobility 
with ≤1 risk factor for VTE
Mechanical prophylaxis
High risk Immobility with ≥2 risk factors Mechanical and pharmacologic (to be considered) 
prophylaxis
Mahajerin  
et al. (13)
Children 
>12 years old
Low risk No risk factors for VTE Early ambulation
Moderate risk Combinations of risk factors for VTE determine moderate 
versus high risk
Mechanical prophylaxis
High risk Mechanical and pharmacologic prophylaxis
VTE, venous thromboembolism.
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placebo, in reducing the incidence of VTE in targeted high-risk 
populations. It is possible that VTE is also preventable in children. 
In fact, the Solutions for Patient Safety network, a national col-
laborative of children’s hospitals in the United States, has aimed 
to reduce harm from hospital-acquired VTE (8). However, in 
contrast to adults, data are lacking to support the use of phar-
macologic prophylaxis in children. Pediatric RCTs of prophylaxis 
have focused on central venous catheter (CVC)-associated DVT 
(CADVT) because this is the most important cause of DVT in 
children. In a systematic review of RCTs of CADVT, Vidal et al. 
analyzed two RCTs on heparin-bonded CVC, three on infusions 
of unfractionated heparin at doses of ≤10 U/kg/h, one on revi-
parin [a low molecular weight heparin (LMWH)] at prophylactic 
dose, one on warfarin, one on antithrombin concentrate, and one 
on nitroglycerin (9). None of them were efficacious. Relative risks 
of CADVT with intervention ranged from 0.06 to 1.53, none of 
which were statistically significant. Despite the lack of supporting 
evidence, hospital-based initiatives are being undertaken to try 
to prevent VTE in children. In this study, we sought to review 
the different published guidelines on the prevention of VTE in 
hospitalized children.
MeTHODS
We searched MEDLINE (OvidSP) for studies from inception 
of the database until September 2016. With a medical research 
librarian, we developed, refined, and performed the search. We 
searched for VTE AND prevent* AND (child* OR pediatr*) AND 
(algorithm* OR protocol* OR guideline*). We also hand searched 
our personal lists and references of eligible studies. From the list 
of articles, we identified those that reported on a guideline for 
the prevention of DVT in children. Salient characteristics of each 
guideline including target population, risk factors considered, 
intervention, compliance, and frequency of DVT and bleeding 
were abstracted from the full text of the article (Tables 1 and 2).
ReSUlTS
We obtained a total of 55 articles from our literature search. Of 
these, four articles fulfilled our criteria (10–13). An additional 
article was added from our personal list (14).
Braga and Young (10)
Braga and Young proposed a pediatric thromboprophylaxis 
flow chart based on a survey they conducted among PICUs in 
England and Wales, review of their cases of DVT and a formal 
literature review. They recommended that all children in their 
PICUs be assessed daily for VTE while immobile. For this, they 
created a risk assessment table patterned after one that is used 
in adults. Risk factors included CVC, pregnancy, congenital 
heart disease, obesity, malignancy, major trauma, massive burns, 
oral contraceptive pill, prolonged surgery, long term steroids, 
and mechanical ventilation. In low-risk children without any 
risk factors, early mobilization and adequate hydration were 
TABle 2 | Summary of factors used in the stratification of risk of venous thromboembolism (vTe) in the different guidelines.
Risk factors Braga and Young (10) Raffini et al. (11) Hanson et al. (12) Meier et al. (14) Mahajerin et al. (13)
Central venous catheter √ √ √ √ √
Exogenous estrogen √ √ √ √ √
Immobility √ √ √ √ √
Inflammatory disease √ √ √ √
Lower extremity trauma √ √ √ √
Obesity √ √ √ √
Prior VTE √ √ √ √
Infection √ √ √
Malignancy √ √ √
Spinal cord injury √ √ √
Thrombophilia √ √ √
Burns √ √
Cardiac disease √ √
Family history of VTE √ √
Lower extremity surgery √ √
Mechanical ventilation √ √
Nephrotic syndrome √ √
Pregnancy √ √
Admission to the intensive care unit √
Asparaginase therapy √
Cardiopulmonary resuscitation √
Hyperosmolar therapy √
Inotropes √
Low Glasgow Coma Score √
Major surgery √
Parenteral nutrition √
Prolonged hospital stay √
Sickle cell disease √
Steroids √
3
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recommended. In addition to these, mechanical prophylaxis was 
recommended for at-risk children defined as those with any risk 
factor. Short-term CVCs should be removed within 24 h unless 
a physician documents that it should remain. Anticoagulation 
with LMWH should be considered for children with burns. 
However, a consultant had to make the decision to anticoagulate. 
Compliance with the protocol and frequency of DVT or bleeding 
were not reported.
Raffini et al. (11)
As part of a patient safety and quality improvement initiative that 
began in response to several adolescent and young adults with 
hospital-acquired lower extremity DVT and PE, Raffini et  al. 
used local data, published adult guidelines, and expert consensus 
to develop institutional recommendations for VTE prophylaxis. 
This initiative was targeted at hospitalized children ≥14  years 
old. In their guideline, the mobility status played an important 
criterion for risk stratification. Children ≥14 years old who were 
mobile during their stay were considered low risk and ambulation 
was encouraged. Children ≥14 years who had altered mobility 
were assessed for additional prothrombotic risk factors (i.e., 
obesity, estrogen, major surgery, burns, trauma, thrombophilia, 
nephrotic syndrome, prior VTE, inflammatory disorders, and 
infection). They were considered at risk for VTE if none of the 
additional prothrombotic risk factors were present, and high 
risk if at least one additional risk factor was present. Mechanical 
prophylaxis was recommended for at-risk children, while children 
who were at high risk were recommended to receive mechanical 
and/or pharmacologic prophylaxis. Contraindications for phar-
macologic prophylaxis were included in the guideline. Dosing 
strategies for anticoagulation were largely extrapolated from 
adult recommendations (30 mg enoxaparin twice daily for high-
risk orthopedic surgery patients, and 40  mg enoxaparin daily 
for medical patients for those >60  kg). The recommendations 
also included placement of sequential compression devices in all 
children ≥14 years old undergoing surgical procedures >45 min 
duration.
Compliance with the recommendations improved from 22 
to >80% over the 4-year study period. A follow-up prospective 
study evaluating bleeding in 89 patients who received enoxaparin 
reported two major bleeding events and five minor bleeding 
events, all in children who underwent major orthopedic surgery 
(15). Therefore, the risk of major bleeding in the orthopedic 
surgery patients was 4% (2/51) and 0% (0/38) in the remaining 
patients. No child developed a non-CADVT.
Hanson et al. (12)
Hanson et  al. reported on a guideline for VTE prophylaxis in 
children admitted to the PICU after trauma. Based on the guide-
line, children were classified into three categories: high risk of 
VTE and without high risk of bleeding, high risk of VTE and 
with high risk of bleeding, and low risk of VTE. Risk factors 
for VTE were projected prolonged immobility, low Glasgow 
Coma Scale score, presence of CVC, spinal cord injury, com-
plex lower extremity fracture, operative pelvic fracture, use of 
inotropes, cardiopulmonary resuscitation, exogenous estrogen, 
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chronic inflammatory state, history of previous DVT, known 
thrombophilia, and current malignancy. High risk of VTE was 
defined as age >13  years or age <13  years with four or more 
risk factors for VTE. Low risk of VTE was age <13  years and 
three or fewer risk factors for VTE. Risk factors for bleeding were 
intracranial bleed, solid organ injury, planned surgical interven-
tion, or invasive procedure in the next 24 h, heparin allergy, high 
risk of severe bleeding, and renal failure. The presence of one 
or more risk factors for bleeding classified the patient as high 
risk of bleeding. For patients at high risk of VTE and without 
high risk of bleeding, pharmacologic prophylaxis with LMWH 
and mechanical prophylaxis were recommended. For patients at 
high risk of VTE and with high risk of bleeding, only mechanical 
prophylaxis was recommended. However, screening ultrasound 
for VTE had to be performed if the child was still in the PICU on 
hospital day 7. Therapeutic heparin was started if the ultrasound 
showed VTE and if the bleeding risk has diminished. Children 
at low risk of VTE were not recommended to receive prophylaxis 
nor surveillance ultrasound be performed.
The authors reported a compliance with the guideline of 
93%. Of 169 children, 60 were high risk of VTE and high risk of 
bleeding, 16 high risk of VTE and without high risk of bleeding, 
and 93 low risk of VTE. A total of three (2%) children developed 
asymptomatic DVT detected on surveillance ultrasound. This 
was lower than the 5% with VTE prior to implementation of the 
guidelines. There were no bleeding complications.
Meier et al. (14)
Meier et al. proposed a guideline for use in hospitalized children 
10–17 years old. The recommendations were developed after a 
thorough review of the literature. Based on the guideline, a child 
is considered at low risk of VTE if the child was not expected 
to have prolonged altered mobility and had no risk factors. A 
child was at moderate risk of VTE if the child was not expected 
to have prolonged altered mobility but had risk factor for VTE, 
or was expected to have prolonged altered mobility but at most 
one risk factor for VTE. High risk of VTE was when prolonged 
altered mobility was expected and with at least two risk factors 
for VTE. Risk factors for VTE include bloodstream infection, 
CVC, history of VTE, hyperosmolar state, inflammatory dis-
eases, asparaginase, estrogen use, obesity, oncologic diagnosis, 
hip or knee reconstruction, nephrotic syndrome, thrombo-
philia, multiple lower extremity long bone fracture, complex 
pelvic fractures, and spinal cord injury. For the low-risk group, 
early ambulation was encouraged and risk factors mitigated. 
For the moderate-risk group, use of mechanical prophylaxis 
was recommended in addition to the recommendations for 
the low-risk group. For the high-risk group, pharmacologic 
prophylaxis should also be considered. Absolute and relative 
contraindications to pharmacologic prophylaxis were listed in 
the guideline. The authors did not report the compliance with 
the guideline nor the frequency of DVT and bleeding with the 
use of the guideline.
Mahajerin et al. (13)
Mahajerin et  al. developed a guideline for use in hospitalized 
children >12 years old. For children younger than 12 years old, 
VTE prophylaxis was considered on an individualized basis. 
Based on literature review in children and adults, and statisti-
cal modeling, they ranked the association of different factors 
with VTE and grouped them into two tiers. Tier 1 risk factors 
were those that retained statistical significance in a multivari-
able regression model. This included prolonged immobilization, 
estrogen therapy, and prolonged hospital stay. Additional factors 
added in tier 1 were autoimmune disease with antiphospholipid 
antibody positivity and acute flare, dilated cardiomyopathy, atrial 
fibrillation, single-ventricle physiology, palliative surgical shunts, 
cystic fibrosis with B. cepacia infection, diabetic ketoacidosis, 
inflammatory bowel disease with acute flare, sickle cell anemia, 
history of VTE, known thrombophilia, and myocardial infarction 
in a first- or second-degree relative <50 years old. Tier 2 factors 
were statistically significant in the bivariate analysis but not in 
the multivariable regression model. This included bacteremia, 
obesity, chronic parenteral nutrition, initial PICU admission, 
mechanical ventilation, and other serious bacterial infections. 
The combination of these risk factors identified a child’s risk 
group. Only ambulatory children without risk factors were 
included in the low-risk group. Non-ambulatory children with 
or without a CVC but not any other risk factor classified a child 
as moderate risk. Presence of any other risk factors elevated the 
category to high risk. In the low-risk group, only ambulation was 
recommended. In the moderate-risk group, mechanical prophy-
laxis was also recommended. Mechanical and pharmacologic 
prophylaxis were recommended in the high-risk group unless 
with contraindications. Separate lists of contraindications for 
mechanical and pharmacologic prophylaxis were included in the 
guideline.
For the first 17 months that the guideline was implemented, 
an average of 69% of 149 qualified patients were screened. 
Compliance with the guidelines was not reported. However, none 
of the screened patients developed VTE compared to three cases 
in the 12 months prior to the guidelines. No bleeding events were 
reported with the use of enoxaparin.
DiSCUSSiOn
Although the rate is increasing, VTE is still far less common in 
children than in adults (1, 16). Thus, current recommendations for 
treatment of VTE in children are largely extrapolated from adult 
studies (17). Similarly, many of the prevention strategies discussed 
above were based upon adult guidelines and expert opinion, in 
response to adolescents who developed hospital-acquired VTE 
as well as a national initiative implemented in 2008 by the Joint 
Commission to focus attention on VTE prevention (18). In this 
systematic review, we identified five guidelines for the preven-
tion of VTE in children. The guidelines were mainly targeted at 
adolescents and used various risk-stratification approaches. Over 
20% of patients hospitalized in children’s hospitals are 14 years or 
older and 6% are 18 years or older (11). Furthermore, hospital-
ized adolescents may have multiple risk factors for VTE, rivaling 
those of their adult counterparts. However, adolescents or young 
adults with hospital-acquired, non-CADVT account for a rela-
tively small proportion of VTE in children, while the majority of 
thrombotic events occur in younger children and are associated 
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with CVC (11). Therefore, it is important to recognize that adult 
thromboprophylaxis guidelines are based upon the proven effi-
cacy of anticoagulants to reduce the rate of lower extremity DVT, 
and not necessarily CADVT.
In a recent survey of pediatric hemostasis and thrombosis 
experts in North America, Badawy et  al. showed that approxi-
mately one-third and one-half of their respondents reported 
having guidelines for pharmacologic and mechanical prophylaxis 
against DVT, respectively, in their hospitals (19). The majority of 
the respondents did not support the adoption of universal phar-
macologic prophylaxis. There was significant variability on which 
risk factors influenced the decision to provide pharmacologic 
prophylaxis. Our findings are consistent with this survey. None 
of the published guidelines recommended universal pharma-
cologic prophylaxis. While age and immobility were consistent 
determinants of the risk of VTE across guidelines, there was 
significant variability in the other risk factors considered. It is 
interesting to note that despite being the most common cause of 
DVT in children, the presence of CVC was not a prominent factor 
in the risk-stratification approaches. This is likely related to the 
negative RCTs on pharmacologic prophylaxis against CADVT 
in children (9). In low-risk children, ambulation was the only 
recommended intervention. Mechanical prophylaxis was recom-
mended for moderate risk while pharmacologic and mechanical 
prophylaxis were recommended for the high-risk group if there 
were no contraindications to pharmacologic prophylaxis. The 
choice of prevention strategy likely reflected the perceived safety 
of mechanical prophylaxis, despite its reduced efficacy compared 
to pharmacologic prophylaxis, in children, based on data from 
adults (5–7).
Randomized controlled trials are an ideal way to determine 
the efficacy of an intervention. However, the conduct of RCTs 
of thromboprophylaxis in children has been difficult. A major 
problem is the low numbers of clinically apparent VTE in 
children (9). In hospitalized children, the rate is only 34–58 
cases per 10,000 admissions (1). Thousands of children and 
multiple centers will be needed to successfully complete an 
RCT that will detect a clinically significant reduction in VTE. 
To increase the frequency of the outcome, and thus decrease 
the estimated sample size, ultrasound diagnosed DVT have 
been recommended and used as outcomes in RCTs in adults and 
children (5–7, 9, 20). Because some subjects have asymptomatic 
DVT, using routine ultrasound in a study increases the event 
rate compared to using symptoms to guide which patients are 
evaluated for DVT. The increased event rate leads to the need for 
a smaller sample size to achieve the same power to detect a treat-
ment difference. Aside from the convenience in lowering the 
sample size, the use of ultrasound diagnosed DVT as outcome 
minimizes the risk of ascertainment bias in detecting DVT by 
physical examination alone (20). Venography was frequently 
used to diagnose DVT in adult studies (21). Because of diffi-
culties in performing venography in children, its use has been 
supplanted by ultrasonography. Some practitioners question the 
use of ultrasound-diagnosed DVT as outcome. In a survey of 
pediatric critical care physicians, most stated that asymptomatic 
DVT diagnosed by radiologic imaging alone are not clinically 
significant (22). Long-term outcomes are needed to determine 
whether asymptomatic DVT is a clinically relevant outcome in 
children (23).
If RCTs will be performed to determine the efficacy of 
prophylaxis against DVT in children, innovative study designs 
are needed. For example, a risk-stratified approach that mirrors 
the published guidelines may need to be incorporated into the 
study design. Bayesian study design with adaptive randomization 
is a potential alternative to determine the differential effect of 
mechanical and/or pharmacologic prophylaxis (24). This design 
has the advantage of dropping treatment arms that are likely to 
be futile then direct subjects to promising treatment. Sample size 
decreases because more subjects are enrolled in fewer treatment 
arms. Quasi-experimental designs, such as stepped wedge trials, 
should also be considered. Such a design can enhance participa-
tion because each center is guaranteed to get the intervention at 
some point (25).
In lieu of RCTs, other sources of evidence are needed to inform 
our practice on the prevention of VTE in children. Guidelines 
can provide some of this information because their consistent use 
can minimize variability in practice and increase the replicabil-
ity of results (26). However, it is crucial that data are collected 
accurately. Of the five guidelines reviewed, only two provided 
data on compliance and three provided data on the frequency 
of DVT and bleeding (11–13). Each center on its own is unlikely 
to obtain sufficient numbers of children to prove any statistically 
significant difference. Meta-analysis of data from each of the cent-
ers might be a useful approach to strengthen conclusions about 
the efficacy of VTE prevention strategies. It may be possible to 
perform such analysis because of similarities in the guidelines, 
particularly those of Raffini et al., Meier et al., and Mahajerin et al. 
(11, 13, 14). Comparable historical controls would be required 
to make the analysis robust. This would require careful thought 
to identify appropriate controls. Finally, the Solutions for Patient 
Safety network is collecting high-quality data on patients with 
VTE and strategies are being developed to reduce VTE (8). This 
quality improvement initiative has the potential to identify effec-
tive VTE prevention strategies.
In conclusion, evidence is lacking on the right approach to 
the prevention of VTE in children. RCTs, which are the gold 
standard, are very difficult to conduct. Innovative designs are 
needed to successfully complete these RCTs. Guidelines have 
been developed despite the paucity of evidence to help with 
patient management. These guidelines can be a source of valuable 
information to inform our practice.
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